Figures & data
Figure 1. Model structure. Note. All patients start in the induction phase. Patients can transition to absorbing death health state from any health state. Abbreviations. BSC, best supportive care; EASI, eczema area and severity index.
![Figure 1. Model structure. Note. All patients start in the induction phase. Patients can transition to absorbing death health state from any health state. Abbreviations. BSC, best supportive care; EASI, eczema area and severity index.](/cms/asset/c75ff17c-65ae-40e1-ae0b-b85a97cb5d57/ijme_a_2059220_f0001_b.jpg)
Table 1. Transition probabilities.
Table 2. Utilities.
Table 3. Resource use and costs.
Table 4. Base case results.
Figure 2. Deterministic sensitivity analyses of selected parameters. Note. Upper bound of utility in no response was -£35,198,512.55. Abbreviations. DSA, deterministic sensitivity analyses; dupi, dupilumab; EASI, eczema area and severity index; ICER, incremental cost-effectiveness ratio; upa, upadacitinib.
![Figure 2. Deterministic sensitivity analyses of selected parameters. Note. Upper bound of utility in no response was -£35,198,512.55. Abbreviations. DSA, deterministic sensitivity analyses; dupi, dupilumab; EASI, eczema area and severity index; ICER, incremental cost-effectiveness ratio; upa, upadacitinib.](/cms/asset/f1ab88b8-e4ff-4c27-8cc8-905fcd1f89f5/ijme_a_2059220_f0002_b.jpg)
Figure 3. Deterministic sensitivity analyses of efficacy parameters. Note. Upper bound of probability to achieve EASI 90 with dupilumab was £1,735,169.38. Abbreviations. DSA, deterministic sensitivity analyses; dupi, dupilumab; EASI, eczema area and severity index; ICER, incremental cost-effectiveness ratio; upa, upadacitinib.
![Figure 3. Deterministic sensitivity analyses of efficacy parameters. Note. Upper bound of probability to achieve EASI 90 with dupilumab was £1,735,169.38. Abbreviations. DSA, deterministic sensitivity analyses; dupi, dupilumab; EASI, eczema area and severity index; ICER, incremental cost-effectiveness ratio; upa, upadacitinib.](/cms/asset/d15bf74f-1503-48ee-a438-a04c33f42c18/ijme_a_2059220_f0003_b.jpg)
Table 5. Scenario analyses.
Table 6. Threshold analysis.
![](/cms/asset/c2e7358e-93ca-4681-9ae9-d639ca59990b/ijme_a_2059220_uf0001_b.jpg)